VIGAB-BIOSTAT: Neuronal Injury Panel Substudy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-31

Study Completion Date

2024-08-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this substudy is to collect and analyze control data to characterize the degree of neuronal injury in PASE patients who have not received vigabatrin to later compare with patients who received this therapy and expand data on the utility of the neuronal injury panel for neuroprognostication. Data from this cohort will be compared with the data generated by the treatment cohort in the main VIGAB-STAT study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

NCT04772547

Status Epilepticus, Electrographic Coma

COMPLETED PHASE2

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

NCT01266291

Complex Partial Seizures

TERMINATED PHASE4

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03370120

Drug-Resistant Epilepsy Focal-Onset Seizures

TERMINATED PHASE2

Valproic AcId for Traumatic BRAin INjury Trial

NCT07166393

Moderate Traumatic Brain Injury (TBI) Severe Traumatic Brain Injury

NOT_YET_RECRUITING PHASE2/PHASE3

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

NCT01147003

Partial Onset Seizures

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post anoxic status epilepticus (PASE) is the development of intractable seizures in the post-cardiac arrest period once return of spontaneous circulation (ROSC) has been achieved. Historically, this condition has resulted in nearly 100% mortality, and the subset of patients diagnosed with PASE has been excluded from previous therapeutic trials in status epilepticus. The administration of vigabatrin, a GABA-ergic medication that blocks GABA catabolism, is being investigated as an adjunctive therapy to improve neurologic outcomes in this patient population through the VIGAB-STAT program at the University of Florida.

Neuroprognostication in cardiac arrest patients remains imprecise. Outcomes following cardiac arrest depend on a multitude of factors, from details of cardiac arrest (e.g., downtime and rhythm on arrest) to other factors that influence secondary brain injury-all of which are hard to ascertain from objective clinical and laboratory data. Neuronal and astroglial protein assays have been investigated in this patient population as a novel method of quantifying the degree of neuronal injury and may serve as an objective informant of ongoing secondary brain injury, thus being a helpful neuroprognostic tool. This assay can also demonstrate objectively if a neuroprotectant therapy mitigates secondary brain injury and decreases the overall hypoxic-brain injury burden. However, normative data on these assays on post-cardiac arrest patients suffering PASE are lacking.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Status Epilepticus Cardiac Arrest With Successful Resuscitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vigabatrin-naive

Adults 18 - 80 years of age suffering from post anoxic status epilepticus (PASE) who have not received vigabatrin.

Neuronal Injury Panel

Intervention Type DIAGNOSTIC_TEST

A panel of neuronal and astroglial assays that may be a marker of brain injury.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuronal Injury Panel

A panel of neuronal and astroglial assays that may be a marker of brain injury.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* To be included in the study, subjects must be 18 - 80 years of age
* Non-traumatic cardiac arrest (regardless of non-perfusing rhythm, etiology, or location of arrest) in whom the decision to treat unequivocal electrographic SE (as defined by the American Clinical Neurophysiology Society: having generalized spike/sharp-wave discharges ≥ 3Hz or any evolving pattern reaching \> 4Hz, lasting ≥ 10 minutes, or comprising \> 50% of any hour of recording) has been made,
* Requiring anesthetic infusion for any reason,
* Have reliable arterial access for frequent blood sampling
* Be enrolled and have the first specimen drawn within 48 hours of PASE onset.